Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-08

Clinical Trial Update: ACT34-CMI -- Adult Autologous CD34+ Cells [Phase 2]

View source ↗

Summary

Phase 2 trial update for ACT34-CMI using autologous CD34+ cells in adults with myocardial ischemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ACT34-CMI (CD34+ cellular therapy)

Snippet

Sponsor: Lisata Therapeutics, Inc. | Conditions: Myocardial Ischemia | Phase 2 | Status: COMPLETED | Results posted: 2021-01-08